Healthcare Industry News:  vascular access 

Devices Interventional Cardiology

 News Release - August 15, 2006

Medafor, Inc., Announces the Introduction of MPatcH(R) Vascular Closure Device to International Cardiology Markets

Unique Hemostatic Closure System for Diagnostic and Interventional Cardiologic Procedures Is Based on Medafor's Patented MPH(R) Technology

MINNEAPOLIS, Aug. 15 (HSMN NewsFeed) -- Medafor, Inc., announced today that its MPatcH® vascular closure system will now be available to markets in Europe, Africa, the Middle East, Central and South America and Asia-Pacific. MPatcH® will be marketed through Medafor's subsidiaries in Germany and France and its international distributor network. MPatcH® is distributed in the U.S. by Possis Medical, Inc. (Nasdaq: POSS ).

The MPatcH® is an innovative topical vascular closure system indicated for patients undergoing diagnostic and interventional cardiologic procedures. The patch system employs Medafor's patented Microporous Polysaccharide Hemospheres (MPH®) technology which instantly dehydrates blood at the wound site, creating rapid hemostasis and resilient clotting. This action significantly reduces the necessary time for hemostasis versus manual compression in vascular access procedures.

"MPatcH® received a highly favorable response at the Paris Course on Revascularization in May, and we are very excited about its launch into the international arena," said Gary Shope, Medafor C.E.O. "We have long seen the need for a simple and efficacious closure system for vascular procedures both domestically and internationally. The MPatcH® is not only fast-acting and highly effective; it is the only topically applied closure device utilizing Medafor's MPH® technology, a patented, plant-based hemostat."

Medafor's Arista-AH® surgical powder hemostat has been marketed internationally since 2002. Medafor has filed its PMA application for Arista(TM)-AH surgical hemostat with the FDA, and anticipates U.S. marketing approval before the end of the year. For further information about Medafor's technology, research and products, please visit http://www.medafor.com .

Medafor, Inc., is a privately held Minnesota Corporation based in Minneapolis. The Company was founded in 1999 to develop and market applications for its patented, innovative hemostatic technology.

This release may contain forward-looking statements based on current expectations of future events. If underlying assumptions prove inaccurate, or unforeseen risks or circumstances materialize, actual results could vary materially from expectations and projections stated herein. The Company assumes no obligation to update any forward-looking statements as a result of new information or future developments.

MPH® and MPatcH® are trademarks of Medafor, Inc.


Source: Medafor

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.